Fosun prescribes IPO booster to put HK back on its feet
Shanghai Fosun Pharmaceutical launched an up-to HK$4.60bn ($593.5m) IPO this week, after deliberating over the weekend about its chances. The offer could be the first big listing in Hong Kong in more than two months.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts